4KSP

Crystal Structure of Human B-raf bound to a DFG-out Inhibitor TAK-632

4KSP の概要

• エントリーDOI: 10.2210/pdb4ksp/pdb
• 関連するPDBエントリー: 3Q96 4DBN 4KSQ
• 分子名称: Serine/threonine-protein kinase B-raf, N-{7-cyano-6-[4-fluoro-3-({[3-(trifluoromethyl)phenyl]acetyl}amino)phenoxy]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide (3 entities in total)
• 機能のキーワード: human serine/theronine protein kinase, kinase drug complex, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Nucleus : P15056
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 65753.79

構造登録者

Yano, J.K.,Masanori, O. (登録日: 2013-05-17, 公開日: 2013-07-24, 最終更新日: 2023-09-20)

主引用文献

Okaniwa, M.,Hirose, M.,Arita, T.,Yabuki, M.,Nakamura, A.,Takagi, T.,Kawamoto, T.,Uchiyama, N.,Sumita, A.,Tsutsumi, S.,Tottori, T.,Inui, Y.,Sang, B.C.,Yano, J.,Aertgeerts, K.,Yoshida, S.,Ishikawa, T.
Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives.
J.Med.Chem., 56:6478-6494, 2013

PubMed Abstract: With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivatives based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor 1 and developed a regioselective cyclization methodology for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines. Eventually, we selected 7-cyano derivative 8B (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF. Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2. Reflecting its potent pan-RAF inhibition and slow off-rate profile, 8B demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines. Furthermore, in both A375 (BRAF(V600E)) and HMVII (NRAS(Q61K)) xenograft models in rats, 8B demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body weight loss.

PubMed: 23906342
DOI: 10.1021/jm400778d

実験手法

X-RAY DIFFRACTION (2.93 Å)